Neurocrine Biosciences, Inc. (LON:0K6R)
125.14
-11.32 (-8.29%)
Feb 12, 2026, 4:55 PM GMT
Neurocrine Biosciences Revenue
In the year 2025, Neurocrine Biosciences had annual revenue of $2.86B USD with 21.45% growth. Neurocrine Biosciences had revenue of $805.50M in the quarter ending December 31, 2025, with 28.33% growth.
Revenue
$2.86B
Revenue Growth
+21.45%
P/S Ratio
4.73
Revenue / Employee
$1.59M
Employees
1,800
Market Cap
10.04B GBP
Revenue Chart
* This company reports financials in USD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 2.86B | 505.20M | 21.45% |
| Dec 31, 2024 | 2.36B | 468.20M | 24.81% |
| Dec 31, 2023 | 1.89B | 398.40M | 26.76% |
| Dec 31, 2022 | 1.49B | 355.20M | 31.34% |
| Dec 31, 2021 | 1.13B | 87.60M | 8.38% |
| Dec 31, 2020 | 1.05B | 257.80M | 32.71% |
| Dec 31, 2019 | 788.10M | 336.90M | 74.67% |
| Dec 31, 2018 | 451.20M | 289.57M | 179.16% |
| Dec 31, 2017 | 161.63M | 146.63M | 977.51% |
| Dec 31, 2016 | 15.00M | -4.77M | -24.12% |
| Dec 31, 2015 | 19.77M | - | - |
| Dec 31, 2014 | - | - | - |
| Dec 31, 2013 | 2.92M | -50.22M | -94.51% |
| Dec 31, 2012 | 53.14M | -24.27M | -31.36% |
| Dec 31, 2011 | 77.41M | 43.91M | 131.08% |
| Dec 31, 2010 | 33.50M | 30.55M | 1,034.47% |
| Dec 31, 2009 | 2.95M | -1.02M | -25.71% |
| Dec 31, 2008 | 3.98M | 2.75M | 224.75% |
| Dec 31, 2007 | 1.22M | -38.01M | -96.88% |
| Dec 31, 2006 | 39.23M | -84.66M | -68.33% |
| Dec 31, 2005 | 123.89M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| AstraZeneca | 43.24B |
| GSK plc | 32.67B |
| Haleon | 11.02B |
| Smith & Nephew | 4.33B |
| Hikma Pharmaceuticals | 2.35B |
| Convatec Group | 1.72B |
| CVS Group | 673.20M |
| Genus | 672.80M |
Neurocrine Biosciences News
- 2 days ago - Preview: Neurocrine Biosciences's Earnings - Benzinga
- 6 days ago - Exploring Analyst Estimates for Neurocrine (NBIX) Q4 Earnings, Beyond Revenue and EPS - Nasdaq
- 17 days ago - Neurocrine Biosciences (NBIX) Begins Phase 2 Trial for Tardive Dyskinesia Treatment - GuruFocus
- 17 days ago - Neurocrine Biosciences Initiates Phase 2 Clinical Study Evaluating NBI-1065890 in Adults with Tardive Dyskinesia - PRNewsWire
- 20 days ago - NBIX Stock Rating Update: UBS Lowers Price Target to $178 | NBIX Stock News - GuruFocus
- 21 days ago - Neurocrine Biosciences Announces Conference Call and Webcast of Fourth Quarter and Year-End 2025 Financial Results - PRNewsWire
- 22 days ago - GraniteShares Advisors LLC Sells 3,122 Shares of Neurocrine Biosciences Inc (NBIX) - GuruFocus
- 22 days ago - BAM Wealth Management, LLC Buys 271 Shares of Neurocrine Biosciences Inc (NBIX) - GuruFocus